Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aticaprant 10 mg Adjunctive Therapy in Major Depressive Disorder With Anhedonia
2024-511557-21-00Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Aticaprant 10 mg adjunctive to SSRI/SNRI with Placebo adjunctive to SSRI/SNRI (2 arms). Primary endpoint: Change from baseline to Day 43 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. Started Oct 2024; status: completed.
02
Drugs
aticaprant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2024-511557-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511557-21-00.